News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NPS Pharmaceuticals, Inc. (NPSP) Release: New Peer-Reviewed Publication Offers Guidance for Integrating Gattex® (Teduglutide [rDNA origin]) for Injection into Management of Short Bowel Syndrome



1/30/2013 9:52:17 AM

BEDMINSTER, N.J.--(BUSINESS WIRE)--The Journal of Parenteral and Enteral Nutrition recently published clinical considerations and best-practice recommendations for introducing Gattex® (teduglutide [rDNA origin]) for injection into the management of short bowel syndrome (SBS). The recommendations conclude that integrating Gattex into a coordinated approach to treating SBS may result in more success in rehabilitating the intestine and weaning from parenteral nutrition (PN)/intravenous (IV) fluids in these patients.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES